<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Blondiaux, Nicolas</style></author><author><style face="normal" font="default" size="100%">Moune, Martin</style></author><author><style face="normal" font="default" size="100%">Desroses, Matthieu</style></author><author><style face="normal" font="default" size="100%">Frita, Rosangela</style></author><author><style face="normal" font="default" size="100%">Flipo, Marion</style></author><author><style face="normal" font="default" size="100%">Vanessa Mathys</style></author><author><style face="normal" font="default" size="100%">Karine Soetaert</style></author><author><style face="normal" font="default" size="100%">Kiass, Mehdi</style></author><author><style face="normal" font="default" size="100%">Delorme, Vincent</style></author><author><style face="normal" font="default" size="100%">Djaout, Kamel</style></author><author><style face="normal" font="default" size="100%">Trebosc, Vincent</style></author><author><style face="normal" font="default" size="100%">Kemmer, Christian</style></author><author><style face="normal" font="default" size="100%">Wintjens, René</style></author><author><style face="normal" font="default" size="100%">Wohlkönig, Alexandre</style></author><author><style face="normal" font="default" size="100%">Antoine, Rudy</style></author><author><style face="normal" font="default" size="100%">Huot, Ludovic</style></author><author><style face="normal" font="default" size="100%">Hot, David</style></author><author><style face="normal" font="default" size="100%">Coscolla, Mireia</style></author><author><style face="normal" font="default" size="100%">Feldmann, Julia</style></author><author><style face="normal" font="default" size="100%">Gagneux, Sebastien</style></author><author><style face="normal" font="default" size="100%">Locht, Camille</style></author><author><style face="normal" font="default" size="100%">Brodin, Priscille</style></author><author><style face="normal" font="default" size="100%">Gitzinger, Marc</style></author><author><style face="normal" font="default" size="100%">Déprez, Benoit</style></author><author><style face="normal" font="default" size="100%">Willand, Nicolas</style></author><author><style face="normal" font="default" size="100%">Baulard, Alain R</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420.</style></title><secondary-title><style face="normal" font="default" size="100%">Science</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Science</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2017 03 17</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">355</style></volume><pages><style face="normal" font="default" size="100%">1206-1211</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Antibiotic resistance is one of the biggest threats to human health globally. Alarmingly, multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis have now spread worldwide. Some key antituberculosis antibiotics are prodrugs, for which resistance mechanisms are mainly driven by mutations in the bacterial enzymatic pathway required for their bioactivation. We have developed drug-like molecules that activate a cryptic alternative bioactivation pathway of ethionamide in M. tuberculosis, circumventing the classic activation pathway in which resistance mutations have now been observed. The first-of-its-kind molecule, named SMARt-420 (Small Molecule Aborting Resistance), not only fully reverses ethionamide-acquired resistance and clears ethionamide-resistant infection in mice, it also increases the basal sensitivity of bacteria to ethionamide.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">6330</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/28302858?dopt=Abstract</style></custom1></record></records></xml>